News Archive

Check out all new posts in our news archive. Click on a headline to read the teaser.

Annate Awarded $400K NCI SBIR Phase I Grant to Advance ANN-01M
Annate Bitherapeutics has been awarded a $400K SBIR Phase I grant from the National Cancer Institute to advance ANN-01M, the company’s lead bispecific antibody program for relapsed/refractory multiple myeloma. Read More ›

University of Georgia Hajduk Lab Awarded IMS and Riney Foundation Translational Research Grant
The University of Georgia’s Hajduk Lab has been awarded a $250,000 International Myeloma Society and Paula and Rodger Riney Foundation Translational Research Grant supporting multiple myeloma research connected to Annate’s platform. Read More ›

Annate Bitherapeutics Wins at the 2026 GIPA Startup Awards
Annate Bitherapeutics won at the 2026 GIPA Startup Awards, recognizing Georgia startups that use intellectual property as a strategic business asset. Read More ›

Eric DeJesus Joins Georgia Life Sciences in Washington for CSBA Fly-In
Annate Bitherapeutics CEO Eric DeJesus, PhD, joined Georgia Life Sciences in Washington, DC, for the Council of State Bioscience Associations Fly-In to advocate for policies that support innovation, patients, and U.S. biotech leadership. Read More ›

UGA Research Profiles Annate Bitherapeutics’ Mission to Help Future Cancer Patients
UGA Research spotlighted Annate Bitherapeutics in a feature on the personal story and scientific mission driving the company’s work to develop new cancer therapies. Read More ›

UGA Research News Highlights Annate Bitherapeutics in Feature on Cancer Innovation
UGA Research News featured Annate Bitherapeutics for its work advancing a bispecific antibody platform designed to harness the innate human immune system against cancer. Read More ›

Annate Bitherapeutics Wins Top Award at UGA Field to Fund: Where Innovation Meets Opportunity
Annate Bitherapeutics earned top recognition and a $2,500 award at the University of Georgia’s Field to Fund: Where Innovation Meets Opportunity event, showcasing breakthrough cancer therapeutics alongside innovators from UGA and the University of Kentucky. Read More ›

CEO Eric DeJesus Wins 2025 UGA Quick Pitch Event
Annate Bitherapeutics CEO Eric DeJesus was named the winner of the 2025 UGA Quick Pitch Event, recognizing his entrepreneurial vision and the company’s innovative cancer therapeutic platform. Read More ›

Annate Bitherapeutics Technology Entered into UGA InPart Portal
Annate Bitherapeutics has been added to the University of Georgia’s InPart technology portal, expanding opportunities for collaboration and industry engagement. Read More ›

Annate Bitherapeutics Wins Pitch Competition at Georgia Life Sciences Summit
Annate Bitherapeutics was named the pitch competition winner at the 2025 Georgia Life Sciences Summit Startup Showcase, earning one-on-one mentorship with the BioTech Execs Network. Read More ›

Annate Bitherapeutics to Present at Georgia Life Sciences Summit 2025
Annate Bitherapeutics has been selected for the Startup Showcase at the 2025 Georgia Life Sciences Summit, joining a prestigious lineup of Georgia-based innovators. Read More ›

Eric DeJesus Featured by ARCS Foundation and ARCS Forward
The ARCS Foundation has recognized Eric DeJesus, PhD, both in a feature article and through his June 2025 ARCS Forward talk on reducing the impact of cancer. Read More ›

Eric DeJesus to Present at ARCS Forward: Reducing the Impact of Cancer
Join ARCS Scholar Alum Eric DeJesus, PhD (Founder & CEO, Annate Bitherapeutics) on June 10 as he discusses innovative cancer-targeting immunotherapies. Read More ›

Annate Bitherapeutics Represents UGA at Southeastern Venture Showcase
The University of Georgia highlighted Annate Bitherapeutics at the inaugural Southeastern Venture Showcase in Nashville, recognizing the company among a select group of early-stage ventures advancing research-driven innovation. Read More ›

Annate Bitherapeutics Chosen to Pitch at Southeast Venture Showcase
The Southeast Venture Showcase is a transformational event that empowers research universities and federal laboratories across the Southeast to showcase their most promising technology ventures for the nation’s venture community. Read More ›

Georgia CTSA Awards Lesinski / Hajduk Lab Funding for Developing Relevant Models for ApoL1 Based Therapies
The Lesinski and Hajduk labs awarded $50,000 to develop relevant models for ApoL1 based therapies. Read More ›

Georgia Research Alliance Awards Annate/Hajduk Lab Phase Ic Funding
In recognition of the significant strides made in Phase Ia and Phase Ib, the Georgia Research Alliance has awarded a $25,000 Phase Ic grant to Annate Bitherapeutics and the Hajduk Lab at the University of Georgia. This grant will specifically support the advancement of proof-of-concept animal studies, a critical step in the development of their innovative therapeutic against Multiple Myeloma. Read More ›

Winship and UGA award pilot grant for pancreatic cancer research
The Winship Cancer Institute of Emory University together with the University of Georgia Cancer Center are delighted to unveil the latest recipients of the Winship-UGA Collaborative Pilot Grant. This prestigious, peer-reviewed award fosters collaboration between faculty members from both institutions, driving forward innovative research in the fight against cancer. This year's grant is dedicated to advancing research in ApoL1 targeted therapies, with a focus on combating pancreatic cancer. Read More ›

Dr. Eric DeJesus, President, Co-founder of Annate Bitherapeutics, Inc. Speaks at ARCs Foundation General Membership Meeting
Over 65 ARCS members and guests gathered at the downtown Capital City Club on January 17, 2024, for one of the most exciting General Membership Meetings in recent memory. Former ARCS Scholar Dr. Eric DeJesus spoke about the formation of his new company, Annate BiTherapeutics, Inc. which is based on the research he began as an ARCS scholar at the University of Georgia. Read More ›

Georgia Research Alliance Awards Annate/Hajduk Lab Phase Ib Funding
In a significant endorsement of innovative cancer research, the Georgia Research Alliance (GRA) has awarded an additional $25,000 in funding to Annate Bitherapeutics, following a triumphant completion of a Phase Ia project. This investment will bolster the collaborative efforts with the Hajduk Lab at the University of Georgia to advance the development of their promising lead therapeutic for combating Multiple Myeloma. Read More ›

Georgia Research Alliance Awards Annate/Hajduk Lab Phase Ia Funding
The Georgia Research Alliance demonstrates its unwavering support for medical innovation by awarding a $25,000 grant to Annate Bitherapeutics in partnership with the Hajduk Lab at the University of Georgia. This strategic funding marks the initiation of Phase Ia in the development of a cutting-edge therapeutic targeting Multiple Myeloma. Read More ›